[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"blog-post-semaglutide-lifespan-mice-zh":3},{"_path":4,"_dir":5,"_draft":6,"_partial":6,"_locale":7,"title":8,"description":9,"cat":10,"icon":11,"accent":12,"date":13,"dateLabel":14,"read":15,"author":16,"image":17,"body":18,"_type":567,"_id":568,"_source":569,"_file":570,"_stem":571,"_extension":572},"\u002Fblog\u002Fzh\u002Fsemaglutide-lifespan-mice","zh",false,"","司美格鲁肽让老年小鼠多活 92 天：这项 Nature 研究说明了什么，又没说明什么","下面是一般性的科普内容，不是医疗建议，也不是鼓励你去弄点什么来用。我们要讲的这项研究是在小鼠身上做的。动物用量推不出人的用量，我们这里也不给任何用量。","研究","tabler:hourglass","#3F8A9B","2026-09-03","2026年9月","10 分钟","myPeptides Team","\u002Fassets\u002Fsema_ageing_hero.png",{"type":19,"children":20,"toc":554},"root",[21,28,33,39,44,124,129,134,139,145,150,155,168,173,200,205,210,215,227,232,237,249,259,280,286,291,303,308,313,318,330,335,370,376,381,386,391,396,401,406,418,423,428,441,461,466],{"type":22,"tag":23,"props":24,"children":25},"element","p",{},[26],{"type":27,"value":9},"text",{"type":22,"tag":23,"props":29,"children":30},{},[31],{"type":27,"value":32},"先说结论：2026 年 9 月 2 日，Nature 上线了一项研究——老年小鼠每天注射司美格鲁肽，中位寿命比对照组长了 92 天，也就是大约 12%。这项工作出自大学实验室，经费来自 NIH 的几笔资助，不是诺和诺德掏的钱。它拿出了一个“少吃就会瘦”解释不了的发现；同时它也有好几个地方，是从小鼠跳到人身上会断掉的。",{"type":22,"tag":34,"props":35,"children":37},"h2",{"id":36},"这项研究测的是什么",[38],{"type":27,"value":36},{"type":22,"tag":23,"props":40,"children":41},{},[42],{"type":27,"value":43},"加州大学伯克利分校 Danica Chen 的团队选的是 20 月龄的雌性小鼠——换算到人身上，大概相当于六十出头。从那时起，这些小鼠每天都要在皮下挨一针：要么是司美格鲁肽，要么是生理盐水。也就是说，对照组同样天天被抓出来扎一下，两组受到的操作应激是一样的。",{"type":22,"tag":45,"props":46,"children":47},"table",{},[48,67],{"type":22,"tag":49,"props":50,"children":51},"thead",{},[52],{"type":22,"tag":53,"props":54,"children":55},"tr",{},[56,62],{"type":22,"tag":57,"props":58,"children":59},"th",{},[60],{"type":27,"value":61},"指标",{"type":22,"tag":57,"props":63,"children":64},{},[65],{"type":27,"value":66},"结果",{"type":22,"tag":68,"props":69,"children":70},"tbody",{},[71,85,98,111],{"type":22,"tag":53,"props":72,"children":73},{},[74,80],{"type":22,"tag":75,"props":76,"children":77},"td",{},[78],{"type":27,"value":79},"中位寿命，对照组（39 只）",{"type":22,"tag":75,"props":81,"children":82},{},[83],{"type":27,"value":84},"742 天",{"type":22,"tag":53,"props":86,"children":87},{},[88,93],{"type":22,"tag":75,"props":89,"children":90},{},[91],{"type":27,"value":92},"中位寿命，司美格鲁肽组（40 只）",{"type":22,"tag":75,"props":94,"children":95},{},[96],{"type":27,"value":97},"834 天",{"type":22,"tag":53,"props":99,"children":100},{},[101,106],{"type":22,"tag":75,"props":102,"children":103},{},[104],{"type":27,"value":105},"差值",{"type":22,"tag":75,"props":107,"children":108},{},[109],{"type":27,"value":110},"92 天，约 12%",{"type":22,"tag":53,"props":112,"children":113},{},[114,119],{"type":22,"tag":75,"props":115,"children":116},{},[117],{"type":27,"value":118},"司美格鲁肽组的进食量",{"type":22,"tag":75,"props":120,"children":121},{},[122],{"type":27,"value":123},"−24%",{"type":22,"tag":23,"props":125,"children":126},{},[127],{"type":27,"value":128},"这个差距在统计上非常明确（P = 5.7 × 10⁻⁶），偶然这个解释基本可以排除。分析里没有剔掉任何一只动物。减掉的体重主要是脂肪，去脂体重的占比还上升了。",{"type":22,"tag":23,"props":130,"children":131},{},[132],{"type":27,"value":133},"你在媒体上有时看到 11%、有时看到 12%，两个都没错：92 天占 742 天是 12.4%，占 834 天是 11.0%——同一个数字，换了个分母而已。新闻稿里说的是“大约 100 天”；准确的数是 92，而且是中位数，不是平均数。",{"type":22,"tag":23,"props":135,"children":136},{},[137],{"type":27,"value":138},"还有一件事几乎所有报道都漏了：研究里其实是三组彼此独立的动物。寿命组那 79 只小鼠，从来没做过运动能力、记忆或干细胞的检测——那几项是另外的队列做的。“活得更久的小鼠同时也更硬朗”这句听着顺理成章的话，研究里一个字都没有，因为没有任何一只动物身上同时量过这两件事。",{"type":22,"tag":34,"props":140,"children":142},{"id":141},"真正的看点和节食比一比",[143],{"type":27,"value":144},"真正的看点：和节食比一比",{"type":22,"tag":23,"props":146,"children":147},{},[148],{"type":27,"value":149},"少喂食能让啮齿动物活得更久，这事从 1930 年代就知道了。所以最直白的解释应该是：司美格鲁肽压住了食欲，小鼠少吃了 24%，说白了就是用针管做的热量限制。",{"type":22,"tag":23,"props":151,"children":152},{},[153],{"type":27,"value":154},"作者恰恰查的就是这一点。他们另设了一组，把一部分动物的口粮精确减到和司美格鲁肽组自己少吃的一样多——同样是 24%，只不过一个靠食盆控制，一个靠食欲。在随后的五个月里，研究者对这两组加上一个对照组反复做了测试。",{"type":22,"tag":23,"props":156,"children":157},{},[158,160,166],{"type":27,"value":159},"在自发活动量、转棒平衡、倒挂悬吊和跑台耐力这几项上，司美格鲁肽和节食",{"type":22,"tag":161,"props":162,"children":163},"strong",{},[164],{"type":27,"value":165},"打成平手",{"type":27,"value":167},"——两组都守住了各自的起始水平，而对照组一路下滑。但在另外三项上，司美格鲁肽比节食更好，而且好过了起始水平：陌生环境里的探索行为、迷宫里的空间记忆，以及葡萄糖耐量。两组的体重和脂肪减少幅度相当，所以这几项差别不可能只是省下那点热量造成的。",{"type":22,"tag":23,"props":169,"children":170},{},[171],{"type":27,"value":172},"这是整篇论文里最有意思的发现。而它要打三处折扣，这三处得跟发现本身摆在一起说：",{"type":22,"tag":174,"props":175,"children":176},"ul",{},[177,190,195],{"type":22,"tag":178,"props":179,"children":180},"li",{},[181,183,188],{"type":27,"value":182},"节食组是整项研究里",{"type":22,"tag":161,"props":184,"children":185},{},[186],{"type":27,"value":187},"唯一没有设盲",{"type":27,"value":189},"的部分——喂多喂少，一看就知道。偏偏被引用最多的那个结论，就出自这个最容易受实验者影响的组，用的还是依赖行为观察的终点。",{"type":22,"tag":178,"props":191,"children":192},{},[193],{"type":27,"value":194},"终点有九个左右，每组十只动物，却没有针对这一整族终点做多重比较校正。三个“命中”只能算提出假设，不算优效性的证明。",{"type":22,"tag":178,"props":196,"children":197},{},[198],{"type":27,"value":199},"寿命这一项，压根就没有节食对照。这项研究没法回答司美格鲁肽延长寿命是不是比节食更强。",{"type":22,"tag":34,"props":201,"children":203},{"id":202},"身体里发生了什么",[204],{"type":27,"value":202},{"type":22,"tag":23,"props":206,"children":207},{},[208],{"type":27,"value":209},"作者查了司美格鲁肽是不是拨动了和热量限制同样的那些开关——大方向上是对的：肝脏和肌肉里的 NAD⁺ 升高，多个 Sirtuin 蛋白上调，血里的促生长因子 IGF1 下降，一个受 FOXO 调控的长寿基因转录增强。在肝组织里，炎症和脂代谢相关的程序走低，蛋白质质量控制和胰岛素应答走高。",{"type":22,"tag":23,"props":211,"children":212},{},[213],{"type":27,"value":214},"关于这一段，有两点要说清楚。第一，这不是一次严丝合缝的验证。七种 Sirtuin 并没有全部起反应，而且肝脏和肌肉里起反应的还不是同一批。这里很多结果测的是基因转录层面，每组只有五到六只动物——机制这部分的分量，明显比那条生存曲线要虚。第二，如果你一直在追长寿这条线的讨论：mTOR、AMPK 和雷帕霉素在这篇论文里根本没有出现过。谁要是从这项研究里读出了这几样，那是他自己加进去的。",{"type":22,"tag":23,"props":216,"children":217},{},[218,220,225],{"type":27,"value":219},"还有一个细节很容易被讲反：骨髓里造血干细胞的数量在司美格鲁肽组是",{"type":22,"tag":161,"props":221,"children":222},{},[223],{"type":27,"value":224},"下降",{"type":27,"value":226},"的，不是上升。这被视为好消息，因为这类细胞在衰老过程中会变多、质量却变差。把这个发现说成“干细胞更多了”，就是说反了。",{"type":22,"tag":34,"props":228,"children":230},{"id":229},"肌肉这一问",[231],{"type":27,"value":229},{"type":22,"tag":23,"props":233,"children":234},{},[235],{"type":27,"value":236},"对大多数读者来说，这才是最要紧的问题：它对肌肉、尤其是上了年纪之后的肌肉，到底做了什么？",{"type":22,"tag":23,"props":238,"children":239},{},[240,242,247],{"type":27,"value":241},"老实说，这项研究只回答了一半。",{"type":22,"tag":161,"props":243,"children":244},{},[245],{"type":27,"value":246},"表现",{"type":27,"value":248},"确实更好了——转棒上、倒挂网格的悬吊上、跑台上都是。前两项在按体重校正之后优势依然在；体重轻的动物本来就更容易吊住，这一点已经被扣掉了。",{"type":22,"tag":23,"props":250,"children":251},{},[252,257],{"type":22,"tag":161,"props":253,"children":254},{},[255],{"type":27,"value":256},"没有",{"type":27,"value":258},"测的是：以克为单位的去脂体重。文中只报告了它占体重的百分比——而只要总体重因为掉脂肪而下降，这个比例就必然上升。没有握力测量，没有单块肌肉的重量，也没有组织切片。想从这篇论文里论证“肌肉量保住了”，跟论证相反的结论一样，都缺料。",{"type":22,"tag":23,"props":260,"children":261},{},[262,264,269,271,278],{"type":27,"value":263},"另外还摆着一项方向相反的研究：Karasawa 等人 2025 年在 Cell Metabolism 上报告，用了司美格鲁肽的小鼠肌肉力量输出下降，而且这个下降",{"type":22,"tag":161,"props":265,"children":266},{},[267],{"type":27,"value":268},"不能",{"type":27,"value":270},"只用肌肉量流失来解释。研究设计不同，问的问题也不同——但方向是反着的。把两边同时摆在桌面上，比挑一边站队要诚实。这个问题在人身上的那一面，我们在",{"type":22,"tag":272,"props":273,"children":275},"a",{"href":274},"\u002Fblog\u002Fretatrutide-liver-damage-myths",[276],{"type":27,"value":277},"瑞它鲁肽与肝脏的事实核查",{"type":27,"value":279},"里聊得更细。",{"type":22,"tag":34,"props":281,"children":283},{"id":282},"大脑以及人身上的那次对照检验",[284],{"type":27,"value":285},"大脑——以及人身上的那次对照检验",{"type":22,"tag":23,"props":287,"children":288},{},[289],{"type":27,"value":290},"作者自己特别强调的一个发现和大脑有关：在齿状回——成年大脑里仍会长出新神经元的那个区域——司美格鲁肽组的神经新生明显更活跃。",{"type":22,"tag":23,"props":292,"children":293},{},[294,296,301],{"type":27,"value":295},"不过这条最适合当标题的结论，在人身上已经检验过一次了，结果是阴性。在 EVOKE 和 EVOKE+ 两项研究里，3,808 名早期阿尔茨海默病患者连续两年每天服用司美格鲁肽片剂。主要终点",{"type":22,"tag":161,"props":297,"children":298},{},[299],{"type":27,"value":300},"没有达到",{"type":27,"value":302},"，两项研究都差得明显；原计划的延长期也被中止了。部分炎症和 tau 标志物有轻微改善，另一些标志物甚至变差了。",{"type":22,"tag":23,"props":304,"children":305},{},[306],{"type":27,"value":307},"这并不推翻小鼠那边的发现——两边问的不是同一个问题：人体研究问的是司美格鲁肽能不能刹住已经发病的阿尔茨海默病，而不是它在健康的老化大脑里能做成什么。但这是最顺理成章的一次外推，它在迄今同类规模最大的试验里接受了检验，而且没有成功。",{"type":22,"tag":23,"props":309,"children":310},{},[311],{"type":27,"value":312},"还有一个更朴素的解释，不该被轻轻放过。神经科学家 Tara Spires-Jones 在英国科学媒体中心（Science Media Centre）提醒说，用了药的动物本来就动得更多——而运动对大脑的好处是有据可查的，路子还相当接近，中间根本不需要一个 GLP-1 药物。这项研究没办法排除这种可能。",{"type":22,"tag":34,"props":314,"children":316},{"id":315},"剂量为什么搬不过来",[317],{"type":27,"value":315},{"type":22,"tag":23,"props":319,"children":320},{},[321,323,328],{"type":27,"value":322},"小鼠拿到的是每公斤 10 nmol，",{"type":22,"tag":161,"props":324,"children":325},{},[326],{"type":27,"value":327},"每天",{"type":27,"value":329},"一针，打在皮下，一直打到生命结束。人是每周一针，通常打上几个月到几年，而且大多远不到 60 岁。",{"type":22,"tag":23,"props":331,"children":332},{},[333],{"type":27,"value":334},"你可以试着换算，只是不同的算法给出的答案并不一样。按监管机构惯用的体表面积折算，落到的是已获批维持剂量的那个量级；直接按每公斤体重硬折，小鼠拿到的就是八到十二倍。两个数都没错，只是它们回答的不是同一个问题——真正能比的，是血液里的药物暴露量，而这项研究没有测。司美格鲁肽在人体内大约能停留一周，在啮齿动物体内则要短上几个数量级；正因为如此，动物实验必须天天打。也就是说，小鼠经历的是每天一次的波峰和波谷，而每周一针的人身上是一条基本平坦的血药曲线。这两种模式究竟是哪一种造出了那个效应，没人知道——这项研究根本没测血药浓度。",{"type":22,"tag":23,"props":336,"children":337},{},[338,340,345,347,352,354,360,362,368],{"type":27,"value":339},"这里站得住的说法是：",{"type":22,"tag":161,"props":341,"children":342},{},[343],{"type":27,"value":344},"效应量级可比",{"type":27,"value":346},"——小鼠少吃了 24%，掉的主要是脂肪，这和人身上的量级差不多；",{"type":22,"tag":161,"props":348,"children":349},{},[350],{"type":27,"value":351},"剂量可比",{"type":27,"value":353},"则不成立。想搞明白单位和毫克为什么这么容易搞混，可以看",{"type":22,"tag":272,"props":355,"children":357},{"href":356},"\u002Fmg-ml-iu",[358],{"type":27,"value":359},"毫克、毫升和 IU",{"type":27,"value":361},"；搞错了会发生什么，看",{"type":22,"tag":272,"props":363,"children":365},{"href":364},"\u002Fblog\u002Fglp1-dosing-errors",[366],{"type":27,"value":367},"GLP-1 用药差错",{"type":27,"value":369},"。",{"type":22,"tag":34,"props":371,"children":373},{"id":372},"_12-算多吗",[374],{"type":27,"value":375},"12% 算多吗",{"type":22,"tag":23,"props":377,"children":378},{},[379],{"type":27,"value":380},"要给它找个参照，最合适的是这个领域里被研究得最透的那种抗衰老药物。雷帕霉素在与这项研究相同的生命阶段开始给药，把雌性小鼠的中位寿命延长了大约 15%。所以这里的 12% 属于同一个量级——扎实，但不是往上冒尖的异类。",{"type":22,"tag":23,"props":382,"children":383},{},[384],{"type":27,"value":385},"真正关键的是接下来这点：雷帕霉素是在干预测试计划（Interventions Testing Program）里测出来的。这是美国国立衰老研究所主持的项目，每种化合物都要在三个彼此独立的实验点同时测试，用的是遗传背景各异的小鼠，而且两种性别都测——之所以这么办，恰恰是因为这个领域里单个实验室的结果常常重复不出来。司美格鲁肽不在这些名单上，原因很朴素：那个项目里的化合物是掺在饲料里给的，而一种需要天天注射的肽，塞不进这套流程。",{"type":22,"tag":23,"props":387,"children":388},{},[389],{"type":27,"value":390},"所以这项研究是一个单实验点的结果，用的是单一品系、单一性别的小鼠，每组不到 40 只。寿命变长了，这在统计上很清楚；至于正好是 12%，那只是一个粗略的估计。而选用雌性动物是有意为之，为的是避开雄鼠之间的争斗——雄性那边，干脆就没有数据。",{"type":22,"tag":23,"props":392,"children":393},{},[394],{"type":27,"value":395},"还有一点对这批读者格外要紧，而且没有一篇报道提到：这些小鼠并不胖。它不是肥胖模型，动物吃的是普通饲料，上了年纪也守住了体重。也就是说，这个效应是在没有既往肥胖的前提下出现的。人这边恰好反过来——关于司美格鲁肽的证据，几乎全部来自超重人群。一个六十岁、身材偏瘦的人能不能得到同样的好处，还是说掉体重对他反而成了麻烦，眼下完全没有答案。",{"type":22,"tag":34,"props":397,"children":399},{"id":398},"这项研究是谁出的钱",[400],{"type":27,"value":398},{"type":22,"tag":23,"props":402,"children":403},{},[404],{"type":27,"value":405},"经费来自美国国立卫生研究院的三笔资助，不是厂家出的。诺和诺德的名字在文中一处也没出现。",{"type":22,"tag":23,"props":407,"children":408},{},[409,411,416],{"type":27,"value":410},"但有一条藏在附注里的信息还是得说，而且我们看到的所有报道都没提：加州大学就“GLP-1 受体激动剂用于健康衰老”提交了一份",{"type":22,"tag":161,"props":412,"children":413},{},[414],{"type":27,"value":415},"专利申请",{"type":27,"value":417},"。也就是说，通讯作者所在的机构，对这项研究考察的这个用途本身有经济利益。这不会让数据失效——但你读新闻稿里那些措辞的时候，得把这个背景放进去。",{"type":22,"tag":34,"props":419,"children":421},{"id":420},"结论",[422],{"type":27,"value":420},{"type":22,"tag":23,"props":424,"children":425},{},[426],{"type":27,"value":427},"这是一项好研究，里面有一个真实的发现：一种 GLP-1 药物在生命晚期才开始给药，让老年小鼠活得更久，也放慢了它们的衰退——在大约九项测量指标里的三项上，比省下同样热量的节食做得更好。对衰老研究来说，这是个值得认真对待的结果。",{"type":22,"tag":23,"props":429,"children":430},{},[431,433,439],{"type":27,"value":432},"对你来说，它什么也没有改变。关于司美格鲁肽和人类寿命，眼下没有任何人体数据；最顺理成章的那条大脑外推刚刚失败；肌肉的问题悬着；而这里真正起作用的那套“治疗”，是一天一针打到生命结束。司美格鲁肽是处方药，获批用于治疗肥胖症和 2 型糖尿病——还有哪些肽拿到了批准，可以看我们的 ",{"type":22,"tag":272,"props":434,"children":436},{"href":435},"\u002Ffda-approved-peptides",[437],{"type":27,"value":438},"FDA 已批准肽类清单",{"type":27,"value":440},"。“活得更久”不在其中，而这项研究里也没有任何一处，能当作为此用药的理由。",{"type":22,"tag":23,"props":442,"children":443},{},[444,446,452,454,460],{"type":27,"value":445},"想先搞懂这一类药物到底怎么起作用，从",{"type":22,"tag":272,"props":447,"children":449},{"href":448},"\u002Fwhat-are-peptides",[450],{"type":27,"value":451},"什么是肽",{"type":27,"value":453},"看起；至于这个具体药物的背景，看",{"type":22,"tag":272,"props":455,"children":457},{"href":456},"\u002Fglp1\u002Fsemaglutide",[458],{"type":27,"value":459},"司美格鲁肽",{"type":27,"value":369},{"type":22,"tag":34,"props":462,"children":464},{"id":463},"参考来源",[465],{"type":27,"value":463},{"type":22,"tag":174,"props":467,"children":468},{},[469,482,494,506,518,530,542],{"type":22,"tag":178,"props":470,"children":471},{},[472,474],{"type":27,"value":473},"Feng 等，Nature 2026，",{"type":22,"tag":272,"props":475,"children":479},{"href":476,"rel":477},"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41586-026-10940-7",[478],"nofollow",[480],{"type":27,"value":481},"Late-life semaglutide treatment slows ageing and extends lifespan in female mice",{"type":22,"tag":178,"props":483,"children":484},{},[485,487],{"type":27,"value":486},"Strong 等，Aging Cell 2020，",{"type":22,"tag":272,"props":488,"children":491},{"href":489,"rel":490},"https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002F10.1111\u002Facel.13269",[478],[492],{"type":27,"value":493},"Rapamycin-mediated mouse lifespan extension: Late-life dosage regimes with sex-specific effects",{"type":22,"tag":178,"props":495,"children":496},{},[497,499],{"type":27,"value":498},"Karasawa 等，Cell Metabolism 2025，",{"type":22,"tag":272,"props":500,"children":503},{"href":501,"rel":502},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F40769122\u002F",[478],[504],{"type":27,"value":505},"Unexpected effects of semaglutide on skeletal muscle mass and force-generating capacity in mice",{"type":22,"tag":178,"props":507,"children":508},{},[509,511],{"type":27,"value":510},"Cummings 等，The Lancet 2026，",{"type":22,"tag":272,"props":512,"children":515},{"href":513,"rel":514},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F41865758\u002F",[478],[516],{"type":27,"value":517},"Efficacy and safety of oral semaglutide in early-stage symptomatic Alzheimer's disease (evoke and evoke+)",{"type":22,"tag":178,"props":519,"children":520},{},[521,523],{"type":27,"value":522},"Lincoff 等，New England Journal of Medicine 2023，",{"type":22,"tag":272,"props":524,"children":527},{"href":525,"rel":526},"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2307563",[478],[528],{"type":27,"value":529},"Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)",{"type":22,"tag":178,"props":531,"children":532},{},[533,535],{"type":27,"value":534},"Di Francesco 等，Nature 2024，",{"type":22,"tag":272,"props":536,"children":539},{"href":537,"rel":538},"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41586-024-08026-3",[478],[540],{"type":27,"value":541},"Dietary restriction impacts health and lifespan of genetically diverse mice",{"type":22,"tag":178,"props":543,"children":544},{},[545,547],{"type":27,"value":546},"Harrison 等，Nature 2009，",{"type":22,"tag":272,"props":548,"children":551},{"href":549,"rel":550},"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fnature08221",[478],[552],{"type":27,"value":553},"Rapamycin fed late in life extends lifespan in genetically heterogeneous mice",{"title":7,"searchDepth":555,"depth":555,"links":556},2,[557,558,559,560,561,562,563,564,565,566],{"id":36,"depth":555,"text":36},{"id":141,"depth":555,"text":144},{"id":202,"depth":555,"text":202},{"id":229,"depth":555,"text":229},{"id":282,"depth":555,"text":285},{"id":315,"depth":555,"text":315},{"id":372,"depth":555,"text":375},{"id":398,"depth":555,"text":398},{"id":420,"depth":555,"text":420},{"id":463,"depth":555,"text":463},"markdown","content:blog:zh:semaglutide-lifespan-mice.md","content","blog\u002Fzh\u002Fsemaglutide-lifespan-mice.md","blog\u002Fzh\u002Fsemaglutide-lifespan-mice","md"]